Ken Griffin Macrogenics Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Macrogenics Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 66,400 shares of MGNX stock, worth $216,464. This represents 0.0% of its overall portfolio holdings.

Number of Shares

66,400

Previous 56,900 16.7%

Holding current value

$216,464

Previous $241,000 9.54%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.31 - $18.51 $1.14 Million - $6.4 Million	-345,665 Reduced 94.9%	18,569 $78,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $1.78 Million - $3.9 Million	181,750 Added 99.6%	364,234 $5.36 Million
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $322,120 - $726,929	71,902 Added 65.02%	182,484 $1.76 Million
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $608,034 - $840,119	-135,722 Reduced 55.1%	110,582 $515,000
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $12,326 - $20,116	-2,668 Reduced 1.07%	246,304 $1.32 Million
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $1 Million - $1.51 Million	-208,072 Reduced 45.53%	248,972 $1.79 Million
Q4 2022 Feb 14, 2023	SELL	$3.34 - $6.98 $26,669 - $55,735	-7,985 Reduced 1.72%	457,044 $3.07 Million
Q3 2022 Nov 14, 2022	SELL	$3.01 - $5.22 $1.89 Million - $3.28 Million	-627,420 Reduced 57.43%	465,029 $1.61 Million
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $2.21 Million - $9.83 Million	984,387 Added 910.95%	1,092,449 $3.22 Million
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $299,692 - $623,745	36,908 Added 51.87%	108,062 $952,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $21.88 $12.8 Million - $17.6 Million	-802,879 Reduced 91.86%	71,154 $1.14 Million
Q3 2021 Nov 15, 2021	BUY	$19.74 - $28.7 $1.7 Million - $2.48 Million	86,255 Added 10.95%	874,033 $18.3 Million
Q2 2021 Aug 16, 2021	SELL	$20.49 - $35.63 $31.4 Million - $54.6 Million	-1,532,738 Reduced 66.05%	787,778 $21.2 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $12.9 Million - $22.6 Million	679,255 Added 41.39%	2,320,516 $73.9 Million
Q4 2020 Feb 16, 2021	BUY	$19.41 - $26.0 $20.7 Million - $27.8 Million	1,068,686 Added 186.65%	1,641,261 $37.5 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $6.17 Million - $7.9 Million	250,096 Added 77.55%	572,575 $14.4 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $57,636 - $322,766	11,084 Added 3.56%	322,479 $9 Million
Q1 2020 May 15, 2020	BUY	$4.28 - $12.11 $264,777 - $749,173	61,864 Added 24.79%	311,395 $1.81 Million
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $1.18 Million - $1.83 Million	-148,802 Reduced 37.36%	249,531 $2.71 Million
Q3 2019 Nov 14, 2019	BUY	$12.44 - $17.48 $4.7 Million - $6.61 Million	377,984 Added 1857.51%	398,333 $5.08 Million
Q2 2019 Aug 14, 2019	SELL	$14.51 - $19.71 $8.56 Million - $11.6 Million	-590,094 Reduced 96.67%	20,349 $346,000
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $5.69 Million - $13.1 Million	511,876 Added 519.32%	610,443 $0
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $418,370 - $762,680	-35,606 Reduced 26.54%	98,567 $1.25 Million
Q2 2018 Aug 10, 2018	BUY	$19.78 - $24.67 $693,150 - $864,510	35,043 Added 35.35%	134,173 $0
Q1 2018 May 11, 2018	BUY	$18.89 - $32.46 $814,177 - $1.4 Million	43,101 Added 76.93%	99,130 $2.49 Million
Q4 2017 Feb 09, 2018	SELL	$16.19 - $20.3 $484,048 - $606,929	-29,898 Reduced 34.79%	56,029 $1.06 Million
Q3 2017 Nov 09, 2017	BUY	$15.52 - $18.94 $1.33 Million - $1.63 Million	85,927	85,927 $1.59 Million

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account